维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

9篇 您的检索式：作者名="Truemper"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Chylothorax and nephrotic syndrome 显示文摘	Solans CV Truemper E Bueton D	1996	Clin Pediatr Phila1996，35，8：	1
	2	A novel dehydroascorbate reductase from spinach chloroplasts homologous to plant trypsin inhibtor显示文摘	TRUEMPER S FOLLMAN H HAEBERLEIN I	1994	FEBS Letters1994，352，：	1
	3	Does the use of an assistive device by nurses impact peripheral intravenous catheter insertion success in children?显示文摘	Peterson KA Phillips AL Truemper E	2012	Journal of pedi- atric nursing2012，27，2：	1
	4	First analy-sis of the comp- letedMabthera International (MINT) trial in youngpatientswith low-ri- sk diffuse large B-cell lymphoma (DLBCL): addition ofrituximab to a CHOP-like regimen silgaificantly im-proves outcome of all patients with the identification of a veryfavorable subgroupwith IPI=0 and no bulky disease显示文摘	Pfreundschuhm Truemper L Gill D	2004	Blood2004，104，48：	1
	5	A Multinational Study of Thromboprophylaxis Practice in Critically Ill Children*显示文摘	Edward Vincent S. Faustino Sheila Hanson Philip C. Spinella Marisa Tucci Sarah H. O’Brien Antonio Rodriguez Nunez Michael Yung Edward Truemper Li Qin Simon Li Kimberly Marohn Adrienne G. Randolph	2014	Critical Care Medicine2014，，5：	1
	6	CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:a randomised controlled trial by the MabThera International Trial (MInT) Group显示文摘	Pfreundschuh M Truemper L Osterborg A	2006	Lancet Oncol2006，7，：	1
	7	Fist analysis of the completed mabthera imemational (MINT) trial in yong patients with tow - risk diffuse large B - cell lymphoma (DL- 13CL) : Addition of rituximab to a CHOP- like regimens sig- nlficandy improves outcome of al padems with the identifica- tion of a very favoralale subgroup with and no 10ulky disease 显示文摘	Pfreundschuch M Truemper L Gill D	2004	Blo:d2004，100，：	1
	8	First analysis of the completed Mabthera International (MINT) trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL) : addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI = 0 and no bulky disease 显示文摘	PFREUNDSCHUH M TRUEMPER L GILL D	2004	Blood2004，104，48：	1
	9	2-weeky or 3-weekly CHOP with and without etoposide for patients ^60 years of age with aggressive non-Hodgkin's lymphoma(NHL):results of the completed NHL-B-2 trail of the DSHNHL显示文摘	Pfreundschuh M Truemper L Kloess M	2002	Ann Oncol2002，13，2：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费